New Study May Prove Risperdal Gynecomastia Link, Strengthening Claims against Johnson & Johnson
Medical experts at the University of British Columbia may have found a direct correlation between a popular antipsychotic medication and male breast growth in a new study that may prove groundbreaking for men involved in growing Risperdal lawsuit litigation.
According to a recent report, the research was presented March 15th, 2014 to the American Association for Geriatric Psychiatry (AAGP) after its leaders looked at data from a large health claims database. Of tens of thousands of individuals included in the data, men who took Risperdal and Invega were shown to be 69 percent more likely to experience complications associated with gynecomastia, a condition referring to male breast development, than non-users. Patients who took Zyprexa were at a 40 percent increased risk, while users of Seroquel were 41 percent more likely to experience male breast development than patients not taking the antipsychotic.
Risperdal Gynecomastia Findings May Impact Pennsylvania Litigation
When these findings are published, they may impact hundreds of Risperdal gynecomastia lawsuits filed in a consolidated litigation in Pennsylvania. These claims are pending in the Philadelphia Court of Common Pleas, and were brought on behalf of men and young boys who used the atypical antipsychotic medication to treat schizophrenia, bipolar disorder and other conditions. Risperdal is manufactured by Johnson & Johnson and distributed by its subsidiary, Janssen Pharmaceuticals Inc., who has also been accused of promoting this and other drugs for uses not approved by the U.S. Food and Drug Administration (FDA). Court documents from March 2014 show more than 200 cases filed in Pennsylvania state court.
Plaintiffs in Risperdal gynecomastia suits are not the only ones questioning the marketing practices of these companies, however. In a settlement reached in November 2013 with the U.S. Department of Justice, Johnson & Johnson agreed to pay over $2.2 billion to resolve claims involving this medication, along with certain others. Risperdal may have been promoted for use in children, and to elderly patients with dementia, according to the federal government, which points out that the FDA did not clear the medication for pediatric uses until 2006.
In addition to this national settlement, several jurisdictions throughout the U.S. have filed federal complaints against Johnson & Johnson. On January 28th, the company successfully appealed a $258 million Louisiana Supreme Court decision that made misleading claims about Risperdal’s safety and efficacy.
Filing a Risperdal Lawsuit
If you or a loved one experienced Risperdal gynecomastia after taking this widely-used antipsychotic, call our Firm at (877) 779-1414.